TabletsClinical Overview
Montelukast Sodium (10mg) and Fexofenadine Hydrochloride (120mg Tablets, Suspension) is a non-sedating dual antiallergic combination. Fexofenadine is a pure second-generation H1-receptor antagonist that does not cross the blood-brain barrier (completely non-sedating), while montelukast blocks cysteinyl leukotriene CysLT1 receptors. Indicated for relief of symptoms associated with allergic rhinitis (sneezing, runny nose, itchy/watery eyes, nasal congestion) in patients needing daytime alertness.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Take orally 1 tablet once daily with water, with or without food. Avoid taking with fruit juices (grapefruit, apple, orange) which inhibit intestinal OATP1A2 transporters and reduce fexofenadine absorption by >35%.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Headache, nausea, dizziness, fatigue, upper respiratory tract infection. Rare/Severe: Neuropsychiatric symptoms and severe hypersensitivity.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Black Box Warning for montelukast neuropsychiatric events. Do not consume with fruit juices. Non-sedating formulation ideal for drivers, pilots, and machinery operators.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, pulmonological diagnosis, or respiratory management recommendations. Inhalation therapies and allergy medications should be used strictly under the guidance of a qualified pulmonologist or registered medical practitioner.
Fexofenadine Hydrochloride Tablets 120mg
Fexofenadine Hydrochloride Tablets (120mg, 180mg) and Suspension (30mg/5ml) is a pure, non-sedating second-generation H1-receptor antagonist on the WHO Model List of Essential Medicines. It is the active carboxylic acid metabolite of terfenadine, but completely lacks terfenadine's cardiotoxicity (does NOT block cardiac HERG potassium channels or cause QT prolongation/Torsades de Pointes). Does not cross the blood-brain barrier. Indicated for relief of symptoms associated with seasonal allergic rhinitis (120 mg once daily) and chronic idiopathic urticaria (180 mg once daily).
Fexofenadine Tablets 180 mg
Fexofenadine Hydrochloride Tablets (120mg, 180mg) and Suspension (30mg/5ml) is a pure, non-sedating second-generation H1-receptor antagonist on the WHO Model List of Essential Medicines. It is the active carboxylic acid metabolite of terfenadine, but completely lacks terfenadine's cardiotoxicity (does NOT block cardiac HERG potassium channels or cause QT prolongation/Torsades de Pointes). Does not cross the blood-brain barrier. Indicated for relief of symptoms associated with seasonal allergic rhinitis (120 mg once daily) and chronic idiopathic urticaria (180 mg once daily).
Montelukast Sodium Tablets 5mg
Montelukast Sodium Tablets (5mg, 10mg) is an oral selective and competitive cysteinyl leukotriene receptor-1 (CysLT1) antagonist on the WHO Model List of Essential Medicines. It blocks the binding of LTD4 (and LTC4/LTE4) to CysLT1 receptors on airway smooth muscle cells, bronchial mucosal endothelial cells, and eosinophils, inhibiting leukotriene-mediated bronchoconstriction, mucous hypersecretion, vascular permeability, and eosinophil migration. Indicated for prophylaxis and chronic treatment of bronchial asthma in adults and pediatric patients >=6 months, prevention of exercise-induced bronchoconstriction, and relief of symptoms of allergic rhinitis.
Montelukast Sodium Tablets 10mg
Montelukast Sodium Tablets (5mg, 10mg) is an oral selective and competitive cysteinyl leukotriene receptor-1 (CysLT1) antagonist on the WHO Model List of Essential Medicines. It blocks the binding of LTD4 (and LTC4/LTE4) to CysLT1 receptors on airway smooth muscle cells, bronchial mucosal endothelial cells, and eosinophils, inhibiting leukotriene-mediated bronchoconstriction, mucous hypersecretion, vascular permeability, and eosinophil migration. Indicated for prophylaxis and chronic treatment of bronchial asthma in adults and pediatric patients >=6 months, prevention of exercise-induced bronchoconstriction, and relief of symptoms of allergic rhinitis.